Jeremy Rupon

Clinical Group Lead
Pfizer Inc.
Collegeville, Pennsylvania, United States

Presentation(s):

• OC 30.5 - Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: updated results from the phase 3 BENEGENE-2 gene therapy trial

  Monday, June 24, 2024
  10:30 – 10:45 ICT